Alterations of the retinoblastoma and/or the p53 signaling network are associated with specific cancers 28 such as high-grade astrocytoma/glioblastoma, small cell lung cancer (SCLC), choroid plexus tumors and 29 small-cell pancreatic neuroendocrine carcinoma (SC-PaNEC). However, the intricate functional 30 compensation between RB1 and the related pocket proteins RBL1/p107 and RBL2/p130 in suppressing 31 tumorigenesis remains poorly understood. Here we performed lineage-restricted parallel inactivation of 32 rb1 and rbl1 by multiplex CRISPR/Cas9 genome editing in the true diploid Xenopus tropicalis to gain 33 insight into these in vivo compensatory mechanisms. We show that while rb1 inactivation is sufficient to 34 induce choroid plexus papilloma, combined rb1 and rbl1 inactivation is required and sufficient to drive 35 SC-PaNEC, retinoblastoma and astrocytoma. Further, using a novel Li-Fraumeni syndrome-mimicking 36 tp53 mutant X. tropicalis line, we demonstrate increased malignancy of retinoblastoma-mutant neural 37 malignancies upon concomitant inactivation of tp53. Interestingly, although clinical SC-PaNEC samples 38 are characterized by abnormal p53 expression or localization, in the current experimental models, the 39 tp53 status had little effect on the establishment and growth of SC-PaNEC, but may rather be essential 40 for maintaining chromosomal stability. SCLC was only rarely observed in our experimental set-up, 41 indicating requirement of additional or alternative oncogenic insults. In conclusion, we used CRISPR/Cas9 42 to delineate the tumor suppressor properties of Rbl1 and generate new insights in functional 43 compensation within the retinoblastoma protein family in suppressing pancreatic and specific neural 44 cancers. 45 Keywords 46 p107, p53, CRISPR/Cas9, Pancreatic neuroendocrine carcinoma, choroid plexus, retinoblastoma, Xenopus 47 tropicalis 48 49 50
Introduction
breast cancer and adrenocortical carcinoma, as well as other less frequent cancers 23 . Previously, Tp53 82 knockout mouse models have been generated and were shown to be prone to the development of a 83 variety of cancers, most frequently lymphomas and sarcomas [24] [25] [26] . Additionally, LFS was modeled in tp53 84 mutant zebrafish spontaneously developing malignant peripheral nerve sheet tumors (MPNST) and 85 angiosarcoma, next to other tumor types 27, 28 . 86
As mentioned before, p53 is an established gatekeeper for numerous tumor types. Hence, 87 experimental oncogenic insults, either genetic or environmental, are frequently employed in a Tp53 88 mutant background because it increases tumor penetrance and reduces tumor latency. As such, we also 89 performed parallel perturbation of the retinoblastoma and p53 signaling network, by multiplexing rb1, 90 rbl1 CRISPR/Cas9 and inactivating tp53 by either CRISPR/Cas9 multiplexing or breeding efforts. We 91 investigated whether sensitizing Xenopus tropicalis to cancer development by perturbing p53 functions 92 could alter the tumor spectrum occurring upon perturbations in the retinoblastoma signaling network. In 93 this regard, previous work also described that concomitant perturbation of the retinoblastoma and p53 94 signaling network generates chromosomal instability (CIN), possibly sensitizing to cancer development 29-95 31 . 96
By our in vivo gene editing strategy we identify novel cell-type specific requirements for inactivation 97 of rbl1, in order to bypass compensation in the native and immunocompetent Xenopus brain and 98 pancreas upon inactivation of rb1, across different tp53 genotypes. By combinatorial CRISPR/Cas9 99 editing of rb1 and rbl1 we demonstrate highly penetrant development of SC-PaNEC, glioblastoma, 100 choroid plexus tumors, next to other cancer types. Interestingly, we provide genetic evidence 101 establishing rbl1 as a genuine tumor suppressor in SC-PaNEC and glioblastoma. 102
We believe our novel genetic X. tropicalis genetic cancer models have the potential to generate 103 important molecular insights and could emerge as promising preclinical cancer models 32 . Namely, these 104
Xenopus cancer models are uniquely positioned as an alternative to viral vector-mediated CRISPR/Cas9 105 mice models, mainly due to the relative ease of CRISPR/Cas9 delivery and the short latency and high 106 penetrance of cancer development 33 . 107 Results 108 tp53 mutant X. tropicalis develop hematological malignancy and sarcomas reminiscent of Li-Fraumeni 109 syndrome 110
In order to generate a tp53 mutant X. tropicalis line, we unilaterally injected tp53 coding region 1 111 (tp53 cr1 ) gRNA precomplexed with recombinant Cas9 protein in two-cell X. tropicalis embryos. Mosaic 112 mutant F0 animals, further called crispants, were raised until sexual maturity and out-crossed with wild-113 type animals. Upon targeted amplicon sequencing and BATCH-GE analysis 34 , we selected two types of F1 114 tp53 heterozygotes, each with a distinct variant of a Δ4 deletion (tp53 Δ4var1/+ and tp53 Δ4var2/+ ) (Table S1A) . 115
Both of these deletions are expected to give rise to nonsense-mediated decay since due to the frame-116 shifting deletion, the pre-mRNA contains a premature stop codon (tp53 168STOP ). These heterozygote 117 mutants (F1) were subsequently intercrossed (tp53 Δ4var1/+ x tp53 Δ4var2/+ ) to obtain F2 homozygous mutant 118 animals (tp53 Δ4var1/Δ4var2 ) (Table S1B ). Both the hetero-and homozygous mutant animals were monitored 119 for morbidity and euthanized at ethical endpoint defined by distended abdomen reminiscent of ascites, 120 lethargy, or decreasing body weight. Of note, X. tropicalis has a significantly longer lifespan than murine 121 animal models and can reach over ten years of age in experimental housing conditions. 122
Kaplan-Meier analysis over a period of 900 days revealed faster occurrence of morbidity in two 123 clutches of tp53 Δ4var1/Δ4var2 (F2) nullizygous animals when compared to tp53 heterozygotes (F1) (p < 0.01; 124 Table S2A ) ( Fig. 1A) . We investigated moribund mutant X. tropicalis by X-ray techniques, revealing 125 calcified ectopic structures in 66% (n=3) of F1 tp53 heterozygous animals ( Fig. 1B) . 126
In order to investigate the possible presence of hematological malignancy, we performed 127 immunohistological analysis of the spleen in moribund tp53 mutant animals. In the wild type Xenopus 128 spleen, CD3 + cells organize in a ring-like structure surrounding the white pulp, which contains the B-cells 129 and displays pronounced PCNA immunoreactivity ( Fig. 1C -left) 35 . However, this CD3 + ring-like structure 130 was disrupted in 75% (n=8) of the moribund tp53 Δ4var1/Δ4var2 animals ( Fig. 1C -right; Fig. 1D ). In 25% (n=8) 131 of these animals we also observed that PCNA immunoreactivity expanded into red pulp areas not 132 contiguous with CD3 immunoreactivity. As such, we conclude that the observed splenic architectural 133 disruptions are reflecting the presence of different hematologic malignancies either or not of the T-cell 134 lineage, which in one case lead to profound cleaved caspase-3 immunostaining in splenic white pulp ( Fig.  135 S1A). Interestingly, both malignancies of the B-and T-cell lineages have been described in murine tp53 136 mutant animals models 36 . 137
In order to further investigate the presence of T-cell-related hematological malignancy in 138 tp53 Δ4var1/Δ4var2 animals, peripheral blood of remaining non-moribund littermates (n=6) was collected by 139 toe clipping and subjected to flow cytometry to investigate the proportion of cells of the T-cell lineage. 140
Enrichment of CD3 + (cytoplasmic or membrane located) and CD8 + cells could be demonstrated in one out 141 of six of the non-moribund animals ( Fig. 1F; Fig. S2-3 ). An increased leukocyte count was subsequently 142 validated by Natt-Herrick's method in blood obtained by cardiac bleed in this animal, when compared to 143 an age-matched control (p < 0.01; Table S2B ) ( Fig. 1E; Fig. S1B ). Furthermore, in this tp53 -/animal, CD3 + 144 cells were also disorganized in the spleen and diffuse dissemination of CD3 + T-lymphocytes could be 145 observed in the liver ( Fig. 1G; Fig. S1C ). Furthermore, we also observed the presence of liposarcoma in 146 one tp53 -/animal ( Fig. S1D) . 147
Finally, one moribund tp53 heterozygous animal presented with a large intraperitoneal lobular 148 neoplasm, classified by histopathology as a high-grade undifferentiated spindled and round cell sarcoma 149 with profound PCNA proliferation marker immunoreactivity ( Fig. 1H) . 150
Taken together, we demonstrate development of a LFS-type tumor spectrum with hematological 151 malignancy and sarcoma in tp53 mutant X. tropicalis, in line with well-characterized Tp53 mutant mouse 152 models 24, 25 . The latency to neoplasm-related morbidity (> 1 year) is relatively long in the tp53 mutant X. 153 tropicalis, but can likely be attributed to the relative long lifespan (~ 10 years) of Xenopus. In any case, 154 these animals constitute a valuable platform for evaluating the role of the tp53 tumor suppressor gene 155 inactivation in combination with other oncogenic insults. Hence, we continued on to target 156 retinoblastoma-family tumor suppressor genes in this tp53 mutant line. 157
Induction of small-cell pancreatic neuroendocrine carcinoma (SC-PaNEC) by CRISPR/Cas9 genome 158 editing 159
In order to investigate the functional consequences of inactivating rb1 and rbl1, under differential 160 tp53 genetic backgrounds, we performed multiplex CRISPR/Cas9-mediated inactivation of these genes in 161 tp53 mutant and wild-type X. tropicalis. Note that the rb1 and rbl1 gRNAs used throughout this study 162 have previously been reported to induce retinoblastoma in X. tropicalis 14 . These gRNAs were shown to 163 induce retinoblastoma independent from CRISPR/Cas9 off-target effects, as in that study another pair of 164 rb1/rbl1 gRNAs with a differential genomic targeting site similarly induced this tumor type. For targeting 165 tp53, we also included a gRNA that was different from the one used to make the KO line, i.e. tp53 coding 166 region 2 or tp53 cr2 . 167
We intercrossed tp53 Δ4var1/+ with tp53 Δ4var2/+ , generating embryos with either tp53 +/+ , tp53 Δ4var1/+ , 168 tp53 Δ4var2/+ or tp53 Δ4var1/Δ4var2 genotype, while simultaneously intercrossing wild-type (WT) X. tropicalis to 169 obtain WT embryos. We subsequently injected tp53 mutant or WT embryos in the eight-cell stage in a 170 single vegetal-dorsal blastomere with distinct combinations of tumor suppressor-targeting CRISPR/Cas9 171 RNPs ( Fig. 2A ). As thus we performed primarily genome editing of the anterior endoderm, including the 172 pancreas. Genome editing was confirmed by targeted amplicon sequencing and BATCH-GE analysis 173 (Table S1C ). Animals were euthanized when presenting with distended abdomen, lethargy and 174 decreasing bodyweight or at end-of-experiment (97 days). Necropsy revealed no gross pancreatic 175 abnormalities in animals resulting from rb1 CRISPR/Cas9 injection in embryos obtained from a tp53 Δ4var1/+ 176 x tp53 Δ4var2/+ intercross (hereafter termed single mosaic knockout (smKO) at 97 days (n=13). However, we 177 observed pancreatic dysmorphology in 86% (n=29) of the animals resulting from multiplexed rb1/rbl1 178 CRISPR/Cas9 injection in embryos obtained from the same intercross (hereafter termed double mosaic 179 knockout (dmKO)) and in 77% (n=22) of the animals resulting from rb1/rbl1/tp53 cr2 CRISPR/Cas9 injection 180 in WT embryos (hereafter termed triple mosaic knockout (tmKO)). Both for dmKO and tmKO, these 181 pancreatic dysmorphologies were observed prior to the 70 day timepoint ( Fig. 2B -C; Table S2C ). preventing SC-PaNEC tumorigenesis. In order to validate this further, we first performed genotyping of 193 tp53 in each dmKO animal and showed that indeed the clutch followed expected Mendelian ratios (H 0 = 194 non-Mendelian; p = 0.63) (Table S1D and S2D) 38 . We observed no correlation between tp53 genotype 195 and incidence of SC-PaNEC development (p > 0.05; Table S2E ) or between SC-PaNEC size and tp53 196 genotype (p > 0.05; Fig. S4A ; Table S2E ). Furthermore, no obvious differences in cell death between tp53 -197 /or tp53 +/+ SC-PaNECs could be demonstrated by TUNEL staining (Fig. S4B ). In fact, SC-PaNEC cells do not 198
show TUNEL positivity, in stark contrast to the immediately surrounding normal pancreatic cells, possible 199 due to cellular stress from the adjacent neoplasm. Finally, investigation of SC-PaNEC proliferation 200 characteristics across different tp53 genotypes, by quantification of pHH3 positive cells in tissue sections, 201 did not reveal any genotype-specific differences ( Fig. S4C ; Table S2F ). 202
Interestingly, the genetic make-up of the tp53 nullizygous mutant animals, with a distinct Δ4 variant 203 on each chromosome, allows assessment of genomic instability on chr3.p. For this, we performed laser 204 capture microdissection (LCM) and tp53 genotyping of SC-PaNECs from the dmKO. We observed 205 chromosomal instability (aneuploidy) involving chr3.p in 66% (n=3) of tp53 -/-SC-PaNECs in the dmKO 206 setup ( Fig. 2F ; Table S1E ; Fig. S5 ). In contrast, tp53 +/-SC-PaNEC (n=3) in the dmKO retained the expected 207 allelic ratios, demonstrating that tp53 LOH is not occurring and that SC-PaNECs can initiate without bi-208 allelic germline mutations in tp53 ( Fig. 2F ; Fig. 2G -blue ovals). Confirming this further, we showed by 209 similar LCM and genotyping methodology that two tumors in the tmKO setup (n=7) developed without 210 biallelic CRISPR/Cas9-mediated inactivation of the tp53 gene (red ovals - Fig. 2G ) . Taken together, we 211 found that inactivation of tp53 is not essential for SC-PaNEC tumor initiation, but provide, albeit 212 preliminary, evidence that its inactivation might drive genomic instability 31 . 213
Rbl1 functions as a tumor suppressor in SC-PaNEC 214
Given that we could not detect any development of SC-PaNECs in smKO (rb1 mosaic mutant) animals, 215 but SC-PaNECs were readily detected in rb1/rbl1 double mosaic mutants (dmKO and tmKO animals), we 216 hypothesized that rbl1 is functioning as a genuine tumor suppressor gene in SC-PaNEC. 217
Previously, multiplex CRISPR/Cas9 technology has been described as a platform enabling in vivo 218 functional interrogation of genes in pancreatic ductal carcinoma 39, 40 . Namely, genes functioning as 219 genuine tumor suppressors are found to be mutated in tumors due to positive selection for inactivating 220 genomic alterations. We had also previously demonstrated similar positive selection pressure on 221 combined rb1 and rbl1 inactivation in a pediatric X. tropicalis retinoblastoma model 14 . 222
We performed LCM of SC-PaNECs, followed by both rb1 and rbl1 genotyping. We could demonstrate 223 fully penetrant positive selection pressure for both rb1 and rbl1 mutations in SC-PaNECs from tmKO 224 (100%; n=7) animals (Table S1F) . Similarly, positive selection for simultaneous rb1 and rbl1 mutations 225 was found in SC-PaNECs from dmKO (100%; n=6) animals ( Fig. 2G) . Overall, our data shows that rb1 226 inactivation alone, irrespective of tp53 genotype, is not sufficient to initiate SC-PaNEC in X. tropicalis. 227
This appears to be due to redundancy with the rbl1 gene, since we demonstrate that inactivation of the 228 retinoblastoma pathway by multiplex rb1/rbl1 inactivation results in highly penetrant SC-PaNEC 229 formation with short latency. 230
Highly penetrant induction of central nervous system tumors in rb1 and rbl1 double mosaic mutants 231
Given the non-necessity for tp53 inactivation in SC-PaNEC development, we further aimed to provide 232 a proof-of-principle that p53 can indeed have tumor suppressive functions in other X. tropicalis Rb1-233 deficient cancers. We performed ectoderm-specific CRISPR/Cas9-mediated genome editing of rb1 and 234 rbl1 in embryos obtained from a tp53 Δ4var1/+ and tp53 Δ4var2/+ intercross, via injection of an animal-dorsal 235 blastomere ( Fig. 3A) (Table S1G ). Animals were euthanized at metamorphic climax (69 days post-236 injection) and necropsy revealed that 75% (n=16) of the animals presented with externally visible 237 retinoblastoma development ( Fig. 3B ). Furthermore, 44% (n=16) of the animals had excessive black skin 238 pigmentation, indicative of a disturbed neuroendocrine reflex in the pituitary or hypothalamus for the 239 regulation of pigment dispersion in dermal melanophores ( Fig. 3B-C) 41 . This prompted us to investigate 240 the animals for CNS abnormalities. Genotyping of tp53 was performed by targeted amplicon sequencing 241 for each animal within the setup (Table S1H ). Histopathology revealed presence of retinoblastoma and 242 brain-located poorly differentiated and highly malignant small blue round cell tumors (SBRCTs), in 243 respectively 75% and 43% (n=16) of the animals, closely recapitulating previously reported 244 retinoblastoma incidences in rb1/rbl1 crispants ( the CNS of tp53 Δ4var1/Δ4var2 animals ( Fig. S6B ). Therefore, we first performed a differential analysis 253 comparing the grade and incidence of choroid plexus tumors across tp53 genotypes. 254
Tp53 mutational status underlies retinoblastoma-mutant choroid plexus tumor progression 255
Having observed the presence of choroid plexus tumors (CPT) in rb1 and rbl1 double crispant tadpoles, 256 we aimed to investigate whether, in line with the clinical data, tp53 inactivation is linked with an 257 increased CPT grade 9 . For this, anonymized sections from choroid plexi (n=15) were analyzed by a 258 pathologist and classified according to clinical WHO grading criteria in one of three categories: normal, 259 grade 1 (G1) (choroid plexus papilloma) or >G1 (atypical choroid plexus papilloma and choroid plexus 260 carcinoma) 44 . Normal amphibian choroid plexus closely resembles the mammalian structural 261 organization, where ependymal cells, capillaries and pia mater can be readily discriminated at high 262 magnification ( Fig. 4A ). G1 neoplasms were characterized by cellular disarray, (pseudo-)stratification and 263 loss of polarization ( Fig. 4A -arrow) , while mitotic figures were relatively rare. In higher grade (>G1) 264 neoplasms, pronounced cellular disarray and severely increased mitotic figures could be observed. Clear 265 continuity between normal choroid plexus (CP) and neoplasms was also demonstrated (Fig. 4B ). By this 266 subclassification, a correlation between tp53 genotype and choroid plexus neoplasm grade could be 267 demonstrated (p < 0.01; Table S2H ) ( Fig. 4C ). Furthermore, immunofluorescence, in a tp53 Δ4var1/Δ4var2 268 animal, further revealed profound PCNA immunoreactivity in a >Grade 1 neoplasm, demonstrating high 269 proliferative activity ( Fig. 4D -white arrow) . 270
Finally, we performed LCM and targeted amplicon sequencing of the tp53 locus in choroid plexus 271 tumors and control tissue ( Fig S7; Table S1I ). As described previously for PaNECs, the genetic make-up of 272 the tp53 homozygous mutant animals allows assessment of genomic instability on chr3.p. In 273 tp53 Δ4var1/Δ4var2 , the >G1 choroid plexus neoplasms exhibited either loss of compound heterozygosity or 274 hyperploidy of one Δ4-variant, while control tissue (normal brain, bone) exhibited the expected normal 275 allelic ratios (50% each variant) ( Fig. 4E -left) . Furthermore, in a high-grade CP lesion in a heterozygous 276 tp53 mutant animal, we could demonstrate LOH of the remaining WT tp53 allele ( Fig. 4E -right). We 277 found lack of positive selection pressure for rbl1 mutations, as we observed that the rbl1 allele remained 278 wild-type in tp53 nullizygous CPTs (n = 3) (Table S1J) Further analyzing the CNS of rb1 and rbl1 multiplex CRISPR/Cas9-engineered animals obtained from a 284 tp53 Δ4var1/+ and tp53 Δ4var2/+ intercross, we also observed the occurrence of glioma with pronounced 285 intratumoral heterogeneity in 81% (n=16) of these animals. A significant correlation between tp53 286 genotype and glioma grade was present, with high-grade glioblastoma lesions only seen in tp53 Δ4var1/Δ4var2 287 animals (p < 0.001) ( Fig. 5A,B ; Fig. S8A ) (Table S2I ). In line with murine Rb1-mutant glioblastoma, high-288 grade lesions were characterized by the presence of pleomorphic giant cells, mitotic defects and massive 289 nuclear aneuploidy ( Fig. 5A, B ) (Supplemental Movie 1) 5,45 . In depth microscopic analysis of these 290 nuclear abnormalities showed some to be interconnected across distances spanning tens of micrometers 291 (Supplemental Movie 2). In the higher grade lesions, the giant cells were also interspersed with smaller 292 rounder cells with dense nuclei. Here, both cell-types possessed a high proliferative index as 293 demonstrated by PCNA immunostaining (Fig. 5E ). Furthermore, we showed heterogeneous 294 immunoreactivity to a GFAP antibody throughout these actively cycling cells, in line with literature and 295 validating astrocytic origin (Fig. S8C) 10 . Glioblastoma cells were observed predominantly in areas 296 contiguous with normal proliferative areas (subventricular zone), especially in the forebrain ( Fig. 5B-C ), but also in regions not immediately spatially associated with such proliferative zones. Areas of 298 pseudopallisading necrosis or hemorrhaging were absent. We found profound EZH2 immunoreactivity in 299 forebrain lesions associated with the SVZ, pointing to a proneural glioblastoma, at least at this 300 anatomical location ( Fig. 5E; Fig. S8B ) 46, 47 . Unfortunately, further attempts to perform glioblastoma 301 subtyping were unsuccessful, due to lack of suitable antibodies in Xenopus tropicalis. 302
The presence of astrocytoma in animals exclusively mutant in rb1 and rbl1 (Fig. 5A, D) , pruned us 303 to investigate whether rbl1 compensates for the loss of rb1, under tp53 wild-type conditions. For this, we 304 performed a retrospective analysis of brain sections from our previously published retinoblastoma study 305 in animals unilaterally targeted at the two-cell stage with rb1 and rbl1 gRNA 14 . We detected the 306 presence of astrocytoma in 100% (n=9) of the animals injected with the rb1/rbl1 gRNAs (Fig. S9) . 307
Astrocytoma was also found in animals injected with another pair of rb1/rbl1 gRNA, ruling out potential 308 CRISPR/Cas9 off-target effects as contributing to the observed phenotype. Interestingly, some 309 astrocytoma lesions in this cohort had spontaneously progressed to high-grade glioblastoma, 310 demonstrating that rb1/rbl1-deficient glioma progression is indeed possible in vivo ( Fig. S9 -black arrow) . 311
We further wanted to investigate whether the requirement for rbl1 inactivating mutations can 312 be overruled by additional oncogenic insults. Co-inactivation of pten was chosen as this gene has been 313 widely linked to glioblastoma malignancy 5,48 . Therefore, we performed ectoderm-specific CRISPR/Cas9-314 mediated genome editing of rb1 and pten cr1 in embryos obtained from a tp53 Δ4var1/+ and tp53 Δ4var1/+ 315 intercross, thus leaving rbl1 intact (Table S1K ). Animals were euthanized at day 42 and histopathology 316 revealed absence of any glioma (0%; n=14) in either of the three tp53 genotypes, including four 317 tp53 Δ4var1/Δ4var1 animals ( Fig. 5D , Table S1L ). In contrast, animals injected with rb1, rbl1, tp53 cr2 and pten cr2 318 in the ectodermal lineage demonstrated complete penetrance in high-grade glioblastoma development 319 (100%; n=13) at day 42 ( Fig. 5C-D ; Table S1M ). 320
Collectively, our experiments provide the direct genetic evidence that rbl1 functions as a tumor 321 suppressor compensating for loss of rb1 in rb1-mutant astrocytes and that concomitant inactivation of 322 rb1/rbl1 is sufficient for glioma initiation. Further, and in line with literature, we demonstrate that tp53 323 inactivation facilitates progression of retinoblastoma-deficient glioma to high-grade glioblastoma 5 . 324 325
Discussion

326
Members of the retinoblastoma pocket protein family (RB1, RBL1, RBL2) play a pivotal role in the 327 control of cellular proliferation and their direct inactivation by mutational events has been previously 328 implicated in cancers, such as small-cell lung carcinoma (SCLC) and retinoblastoma 13,49 . However, 329 contemporary approaches for understanding and modeling cancer has conceptualized that signaling 330 networks can be disturbed at diverse nodes, converging on similar downstream phenotypical 331 consequences. For instance, within the RB signaling network, the ability of RB1 and RBL1 to regulate the 332 cell cycle can be bypassed by events altering their common upstream cyclin dependent kinase regulators 333 (i.e CDK4, CDKN2A/p16). Such direct genetic deregulation of the RB signaling network by either CDK4 334 amplification, or inactivation of CDKN2A/B or RB1, had been previously shown in human SC-PaNEC and 335 glioblastoma 4,50-52 . In contrast, direct genetic inactivation of RBL1 (p107) remains rare (<0.5%) in clinical 336 glioma samples. However, reanalyzing cancer genomic data for combined cohort of 8 glioma studies 337 validated mutual exclusivity between CDNK2A/B and CDK4 alterations (p < 0.001), but established 338 significant co-occurrence of RB1 and RBL1 alterations (p = 0.034) (Table S3) In fact, to our knowledge the definitive genetic in vivo elucidation of RBL1 as a glioma tumor suppressor 351 has not been reported before. Here we showed that rbl1 inactivation is a cooperative event in the rapid 352 establishment of glioma in immunocompetent rb1-deficient Xenopus tropicalis. Furthermore, we believe 353 that while direct genetic inactivation of the RBL1 gene is rare (0.3%) in glioma, additional mechanisms 354 are at play in which the RBL1 protein could in fact be a major player in suppressing tumorigenesis, but 355 has had its role previously seen minimized due to its indirect inactivation at a functional level. 356
We also demonstrate that concomitant inactivation of rb1 and rbl1 is sufficient to induce SC-PaNEC. In contrast to these newly discovered rbl1 tumor suppressor roles, we also show that choroid plexus 364 tumorigenesis does not critically depend on rbl1 inactivation. Additionally, while we had previously and 365 incidentally discovered a small cell lung carcinoma in a rb1/rbl1 crispant 14 , we fail to identify these in 366 larger cohorts of rb1/rbl1 crispants, across different tp53 genotypes. Interestingly, this is in line with 367 mice modeling data placing Rbl2 (p130), and not Rbl1, at the center of tumor suppression in rb1-deficient 368 endocrine lung cells 49 . This reflects, cell-type specific responses to inactivation of distinct retinoblastoma 369 network elements, whose interplay could be further dissected using CRISPR/Cas9 in Xenopus 11 . 370 Furthermore, we also co-interfered with the cell signaling death network by targeting tp53, in order 371 to gain insight in how co-occurring p53 aberrations influences rb1/rbl1-deficient cancers. In contrast to 372 the accepted paradigm that concomitant p53 and retinoblastoma signaling network abnormalities are 373 required to initiate SC-PaNEC, we demonstrate unexpected low impact of tp53 inactivation in rb1/rbl1-374 inactivated SC-PaNEC 2 . In line with our results, the implication of p53 in clinical SC-PaNEC is 375 predominated by abnormal immunostaining of the p53 protein, rather than absence of reactivity, which 376 would be indicative for p53 loss-of-expression 63,64 . We speculate that TP53 mutational events could be 377 dispensable in early SC-PaNEC tumorigenesis, but that TP53 alterations and their consequent 378 chromosomal instability could eventually leads to highly malignant and metastatic SC-PaNEC 29 . 379
Unfortunately SC-PaNEC is considered to be unresectable and mostly metastatic at the time of diagnosis 380 and hence patients are almost immediately treated with chemotherapy, precluding clinical assessment 381 of TP53 alterations in early stages of SC-PaNEC development. Regrettably, the tumors in our Xenopus 382 model are too fast growing, leading to morbidity and ethical endpoint prior to metastasis formation, 383 impeding assessment of this hypothesis. 384
In contrast to the above and closely recapitulating the known roles of p53, we demonstrate that in 385 CPTs and glioblastoma, wild-type X. tropicalis p53 is able to limit tumor progression. Namely, tp53 386 nullizygous choroid plexus tumors and gliomas demonstrate more malignant histological characteristics, 387 higher proliferation and increased chromosomal instability, in line with the published clinical human and 388 mice experimental data 3,9,65 . 389
In this paper we also describe the first tp53 nullizygous X. tropicalis line and demonstrate that 390
Xenopus tp53 behaves, analogous to TP53 in Li-Fraumeni, as a tumor suppressor gene for syndromic 391
Xenopus cancer development. We demonstrate that tp53 mutations are predisposing for a Li-Fraumeni 392 tumor spectrum, namely hematological malignancies and sarcomas, admittingly with a long latency of >1 393
year. We believe the latter to be attributable to the life-span of X. tropicalis that is substantially longer 394 (>3x) than mice and may also underlie interspecies physiological differences. Interestingly, our 395 In the comparison to established mammalian cancer models, we believe that Xenopus holds unique 405 experimental advantages such as extremely straightforward tissue-restrictive CRISPR/Cas9 delivery and 406 multiplexing in externally developing embryos 18 . Additionally, the X. tropicalis SC-PaNEC, glioblastoma 407 and choroid plexus cancer models we report here are competitive with or outperform the existing 408 Rb1/Tp53-inactivated mice models in terms of latency and penetrance of tumor development (Table S4) . 409
In synopsis, we demonstrate the use of tissue-restricted multiplexed inactivation in Xenopus embryos 410 to functionally identify novel tumor suppressor combinations in vivo. This nicely complements AAV-411 mediated in vivo murine CRISPR screens 14,45 . We established novel highly penetrant and short latency 412 genetic X. tropicalis cancer models upon multiplex in vivo CRISPR/Cas9-mediated inactivation of the rb1, 413 rbl1 and tp53 tumor suppressor genes. These models will generate novel opportunities for gene function 414 interrogation, therapeutic target identification and pre-clinical drug studies. Finally, showcasing the 415 possibilities of multiplexed CRISPR/Cas9 in delineating novel driver mutations in cancer, we establish 416 formal proof of rbl1 as a tumor suppressor in glioblastoma and small-cell pancreatic neuroendocrine 417 carcinoma. 418 419
Material and Methods
420
Generation of X.tropicalis mosaic mutants by CRISPR/Cas9 421
All gRNAs were designed with the CRISPRScan algorithm (http://www.crisprscan.org/) 68 . In this study 422 following sequences were targeted. Rb1 5′-GCTGTATGATTGTGCTGTACCGG-3′, rbl1 423 TGGGCTTGCGCGCTGATGTGGGG, tp53 cr1 5'-CCTCAACTGAGGATTACGCAGGG-3', tp53 cr2 5'-424 GAAGAGCTTGTTGAGGTCGGTGG-3', pten cr1 5'-GCGCTTGGGACCTGCTGTTGAGG-3', pten cr2 5'-425 GAGTTACAATTCCCAGCCAAAGG-3'. gRNAs were generated by in vitro transcription, employing the oligos 426 shown in supplementary table 5A, and quality control and quantification was performed as described 427 before 69, 70 . Recombinant NLS-Cas9-NLS protein was generated as previously described 14 . Natural X. 428 tropicalis matings were performed and embryos were microinjected in either the two-or the eight-cell 429 stage with injection mixes containing precomplexed gRNA and Cas9 protein as shown in supplementary 430 table 5B. Approval was obtained from the Ethical Committee for Animal Experimentation, Ghent 431
University, Faculty of Science and VIB-Site Ghent (EC2018-079). All methods were carried out in 432 accordance with the relevant guidelines set out by this committee. 433 Table 1 . 444
Next-generation amplicon sequencing 434
Ex-vivo micro-CT imaging 445
For ex-vivo micro-CT imaging of tp53 heterozygous animals, cone-beam micro-CT was employed 446 (Triumph-II, TriFoil Imaging, Northridge, CA, USA). A high-resolution micro-CT imaging protocol was used 447 with the following acquisition parameters: one bed position (90 mm field of view), circular trajectory 448 with continuous rotation over 360 degrees, 50 µm focal spot size, 50 µm detector pixel size, 1.3 times 449 magnification, 512 projections, 370 µA tube current and 50 kVp tube voltage, resulting in a total 450 acquisition time of 14 minutes. The acquired projection data were reconstructed into a three-451 dimensional image with 512x512x1024 matrix and 100 µm voxel size using the Feldkamp-Davis-Kress 452 algorithm. 453
Flow Cytometry and Natt-Herrick leukocyte counting 454
Peripheral blood was collected from wild-type or mutant X. tropicalis by toe clipping and immediately 455 suspended in cold 0.66x PBS (amphibian PBS or APBS). Cells were fixed for 20 minutes using fresh 2% 456 paraformaldehyde, blocked/permeabilized in 2% Natural Goat Serum, 1% BSA (VWR) and 0.1% Tween 20 457 Table S1 : Genotyping by PCR amplification, sequencing (MiSeq) and BATCH-GE analysis. Genotyping 817 performed throughout this study after BATCH-GE processing with genome editing efficiencies and 818 variant calls, subdivided in letter-coded sheets. 819 Table S2 : Statistical Analyses. Raw data and statistical tests performed throughout this study, subdivided 820 in letter coded sheets. 821 Table S3 : Analysis of co-occurrence of RB1 and RBL1 alterations in human glioma. 822 Table S4 : Comparison between established, closest prior art, mice cancer models and the novel 823
Xenopus models presented in this study in terms of time-to-onset and penetrance of cancer 824 phenotypes. 825 
